Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami SI, Inaba Y, Hanaoka H, Ikeda K, Nakajima H; LoVAS Collaborators. Furuta S, et al. Among authors: sugiyama t. JAMA. 2021 Jun 1;325(21):2178-2187. doi: 10.1001/jama.2021.6615. JAMA. 2021. PMID: 34061144 Free PMC article. Clinical Trial.
Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Furuta S, Sugiyama T, Umibe T, Kaneko Y, Amano K, Kurasawa K, Nakagomi D, Hiraguri M, Hanaoka H, Sato Y, Ikeda K, Nakajima H; LoVAS Trial study investigators. Furuta S, et al. Among authors: sugiyama t. BMJ Open. 2017 Dec 14;7(12):e018748. doi: 10.1136/bmjopen-2017-018748. BMJ Open. 2017. PMID: 29247107 Free PMC article. Clinical Trial.
Latent class analysis of 216 patients with adult-onset Still's disease.
Sugiyama T, Furuta S, Hiraguri M, Ikeda K, Inaba Y, Kagami SI, Kita Y, Kobayashi K, Kobayashi Y, Kurasawa K, Nakagomi D, Nawata Y, Kawasaki Y, Shiko Y, Sugiyama T, Nakajima H. Sugiyama T, et al. Arthritis Res Ther. 2022 Jan 3;24(1):7. doi: 10.1186/s13075-021-02708-3. Arthritis Res Ther. 2022. PMID: 34980244 Free PMC article.
Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray.
Sanayama Y, Ikeda K, Saito Y, Kagami S, Yamagata M, Furuta S, Kashiwakuma D, Iwamoto I, Umibe T, Nawata Y, Matsumura R, Sugiyama T, Sueishi M, Hiraguri M, Nonaka K, Ohara O, Nakajima H. Sanayama Y, et al. Among authors: sugiyama t. Arthritis Rheumatol. 2014 Jun;66(6):1421-31. doi: 10.1002/art.38400. Arthritis Rheumatol. 2014. PMID: 24591094
Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients.
Yamagata M, Ikeda K, Tsushima K, Iesato K, Abe M, Ito T, Kashiwakuma D, Kagami S, Iwamoto I, Nakagomi D, Sugiyama T, Maruyama Y, Furuta S, Jayne D, Uno T, Tatsumi K, Nakajima H. Yamagata M, et al. Among authors: sugiyama t. Arthritis Rheumatol. 2016 Mar;68(3):713-23. doi: 10.1002/art.39475. Arthritis Rheumatol. 2016. PMID: 26474081
Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation.
Iwamoto T, Ikeda K, Hosokawa J, Yamagata M, Tanaka S, Norimoto A, Sanayama Y, Nakagomi D, Takahashi K, Hirose K, Sugiyama T, Sueishi M, Nakajima H. Iwamoto T, et al. Among authors: sugiyama t. Arthritis Care Res (Hoboken). 2014 Oct;66(10):1576-81. doi: 10.1002/acr.22303. Arthritis Care Res (Hoboken). 2014. PMID: 24515410 Free article.
3,815 results